News: UK clinicians welcomed at ATRAD World Congress
A number of clinicians that are using the Swiss DolorClast in the UK travelled to the recent ATRAD World Congress event in Berlin, Germany to mark their registration as ATRAD-certified clinicians.
ATRAD, the Association for Radial Pain Therapy, is a scientific programme that brings Swiss DolorClast users from across the world together on an annual basis to share information about best practice and to discuss their experiences when using the Swiss DolorClast Extracorporeal Shockwave Therapy (ESWT) device.
Spectrum Technology officials were joined by nine clinicians from the UK who travelled to this year’s event in the German capital. More than 200 Swiss DolorClast users from across the world attended the event in total.
“This was the first year that UK clinicians can attend and register as ATRAD-certified clinicians and I know the people that came with us found the whole experience very useful and enlightening,” said Jim Westwood, Spectrum Technology Managing Partner.
“There were lots of discussions to get involved with during the two days of congress and one of those was how to use the Swiss DolorClast most effectively. This focused on the key elements of usage when targeting the best possible clinical outcome for the patient.”
Having unrestricted access to a scientific programme like ATRAD is regarded as a major benefit for the growing number of Swiss DolorClast users in the UK because it gives clinicians vital support.
Westwood explained: “Being able to share information is critical for Swiss DolorClast users because the device is used in lots of different ways by lots of different people. Education and experience is key to the success of the Swiss DolorClast and we’re committed to providing that through ATRAD.”
EDITORS’ NOTES
Spectrum Technology UK Ltd is the exclusive distributor for the Swiss DolorClast Extracorporeal Shockwave Therapy device in the UK
NICE advised that Extracorporeal Shockwave Therapy (ESWT) is considered a safe treatment option for the treatment of Plantar Fasciitis, Achilles Tendonopathy and Tennis Elbow in August 2009
Spectrum Technology's Swiss DolorClast device has amassed more clinical trial data between levels one and two than any other Extracorporeal Shockwave Therapy device in the world
The Swiss DolorClast device is widely used in top-flight sport to treat and manage injuries. The device is used by a number of football teams in the English Premier League and was also used by athletes at the recent Olympic Games in China and Canada
The Swiss DolorClast is the only ESWT device to be actively promoted in the UK that administers low-energy impulses during treatment. As yet, there have been no reported ruptures as a result of using the Swiss DolorClast
The Swiss DolorClast Extracorporeal Shockwave Therapy device was first launched in 2000. It was designed and continues to be manufactured by Electro Medical Systems (EMS) in Switzerland
The Swiss DolorClast device delivers shockwaves to the injured area of the body by converting kinetic energy into a shockwave - an action that is clearly illustrated by Newton's Cradle
Spectrum Technology is proud to conduct its clinical trials with the support of some of the UK's leading medical professionals. This list includes Professor Nicola Maffulli, one of the most pre-eminent sports medicine and orthopaedic consultants in the UK